Afaxys Names Rita O’Connor New Chief Financial and Operations Officer
CHARLESTON, S.C., August 15, 2024 – Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals and their patients, today announced the appointment of Rita O’Connor to Executive Vice President, Chief Financial and Operations Officer (CFO/COO). Rita previously joined the Afaxys Board of Directors and Finance and Audit Committee in February 2024. As Rita transitions into her new role, she will serve as Treasurer of the company, a member of the Executive Team and will oversee every aspect of financial management as well as manufacturing, quality and supply chain.
“On behalf of the Board of Directors and my Executive Team, I am thrilled to announce that Rita will step into her new role as CFO/COO to help us continue to navigate the complexities of our evolving healthcare landscape while we work to advance health equity,” said Ronda Dean, President, CEO & Co-Founder of Afaxys. “Rita’s extensive financial and operations expertise in the pharmaceutical industry and proven leadership will be invaluable as we continue to partner with those who serve public health patients to ensure that access to affordable sexual and reproductive healthcare is a right, not a privilege.”
Rita O’Connor has more than 30 years of experience in financial and operational leadership with both public and private pharmaceutical and consumer products companies. Her previous roles include CFO and Head of Manufacturing and Supply Chain at PLx Pharma Inc., CFO and Chief Information Officer at Xanodyne Pharmaceuticals, Inc., CFO and Treasurer at Adams Respiratory Therapeutics, Inc. and CFO at Kent Place School. Rita has also served as Board Director and Chairperson of the Audit committee for uLab Systems, Inc. and for Essential Group and is a licensed certified public accountant with a Bachelor of Science in accounting from Rutgers University.
“I am looking forward to transitioning into this new role at Afaxys as the company enters an exciting phase of strategic growth,” said O’Connor. “Together with this talented team, we will work to continue to ensure access to high-quality products for patients and further solidify Afaxys’ leadership in public health.”
About Afaxys
Afaxys, Inc., a Public Benefit Corporation, uniquely partners with public health and private industry to ensure healthcare professionals have stable pricing and reliable access to the products and services they need to care for their patients, contributing to a healthier and more empowered society.
The Afaxys enterprise comprises a family of companies that operate under four wholly owned subsidiaries: Afaxys Pharma, LLC, Afaxys Group Services, LLC (AGS), Afaxys Drug Development, LLC and Afaxys Marketplace, LLC.
Forward-Looking Statements
The statements in this press release that are not historical facts constitute “forward-looking statements” as defined by Federal Securities laws. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, risks related to the inability to implement strategic initiatives, and the dependence on key personnel. Forward-looking statements speak only as of the date they are made. Afaxys, Inc. will not update forward-looking statements to reflect factual assumptions, circumstances or events that have changed after a forward-looking statement was made.
Afaxys Media Contact
Green Room Communications
gr_afaxys@grcomms.com